Anebulo reports Q2 fiscal 2023 net loss of $3.8M; Phase 2 trial completed for ANEB-001

Anebulo Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.26

Net loss of $3.8M ($0.15 per share) vs $1.1M ($0.05) in Q2 fiscal 2022.
Cash and cash equivalents of $16.4M as of Dec 31, 2022.
Completed dosing Phase 2 trial for ANEB-001; preliminary data shows 10mg dose reduces key ACI symptoms.
Final Phase 2 data expected by end Q1 2023; End-of-Phase 2A meeting with FDA expected Q2 2023.
Continued development of parenteral formulation of ANEB-001.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Anebulo Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: net income ($3.8 million), EPS $(0.15).

Period: three months ended December 31, 2022
Net income: ($3.8 million)
EPS: $(0.15)
Result: reported results

Exact text from the filing

Net loss in the second quarter of fiscal 2023 was $3.8 million, or $(0.15) per share, compared with a net loss of $1.1 million, or $(0.05) per share, in the second quarter of fiscal 2022.

View on SEC.gov

Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-004202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.